文献速递慢性肾脏病水电解质与酸碱

慢性肾脏病各阶段中慢性肾脏病-矿物质与骨异常的复杂性

The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
PubMed 文献 · Kidney Int · 2017-03-18

本研究评估了CKD 2-3期、CKD 4期、CKD 5期透析患者及健康个体骨组织中多种蛋白的表达,并检测骨重塑标志物与骨活检结果的相关性。随CKD进展,血清钙下降而血磷、碱性磷酸酶、FGF-23、甲状旁腺激素及骨保护素升高,骨吸收逐渐增加并伴骨形成减少和矿化受损。FGF-23与硬骨素在骨组织中不共定位,血清FGF-23水平与骨表达良好相关。

要点

  • 随CKD进展,血清钙下降而血磷、碱性磷酸酶、FGF-23、甲状旁腺激素及骨保护素升高。
  • 骨吸收逐渐增加,同时骨形成减少和骨矿化受损。
  • 硬骨素和甲状旁腺激素受体-1骨表达似乎在CKD早期增加,FGF-23和磷酸化β-连环蛋白在晚期增加。

核心结论

  • 本研究有助于阐明CKD患者骨与矿物质代谢的复杂机制,血清标志物与特定蛋白骨表达的关联可能有助于理解和管理该病。

研究设计与样本

  • 研究纳入CKD 2-3期、CKD 4期、CKD 5期透析患者及健康个体,评估骨组织蛋白表达,检测骨重塑标志物并与骨活检结果做相关性分析。

主要发现

  • 随CKD进展,血清钙下降,血清磷、碱性磷酸酶、FGF-23、甲状旁腺激素及骨保护素升高。
  • 骨吸收逐渐增加,伴骨形成减少和骨矿化受损。
  • 硬骨素和甲状旁腺激素受体-1的骨表达似乎在CKD较早阶段增加,FGF-23和磷酸化β-连环蛋白在CKD晚期表达增加,但所有这些蛋白相对健康个体均升高。
  • 免疫组化显示FGF-23与硬骨素不共定位,提示由不同的骨细胞产生。
  • 血清FGF-23水平与骨表达FGF-23之间相关性良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (CKD-MBD) is a complex disease that is not completely understood. However, some factors secreted by the osteocytes might play an important role in its pathophysiology. Therefore, we evaluated the bone expression of proteins in a group of patients with CKD 2-3, CKD 4, and CKD 5 on dialysis and healthy individuals. We also tested several bone remodeling markers, and correlated these levels with bone biopsy findings. As expected, as serum calcium decreased, serum phosphate, alkaline phosphatase, fibroblast growth factor-23 (FGF-23), parathyroid hormone, and osteoprotegerin increased, as CKD progressed. Additionally, there was a gradual increase in bone resorption associated with a decrease in bone formation and impairment in bone mineralization. Bone expression of sclerostin and parathyroid hormone receptor-1 seemed to be increased in earlier stages of CKD, whereas FGF-23 and phosphorylated β-catenin had increased expression in the late stages of CKD, although all these proteins were elevated relative to healthy individuals. Immunohistochemical studies showed that FGF-23 and sclerostin did not co-localize, suggesting that distinct osteocytes produce these proteins. Moreover, there was a good correlation between serum levels and bone expression of FGF-23. Thus, our studies help define the complex mechanism of bone and mineral metabolism in patients with CKD. Linkage of serum markers to bone expression of specific proteins may facilitate our understanding and management of this disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Graciolli FG, Neves KR, Barreto F, et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017. PMID: 28318623. doi:10.1016/j.kint.2016.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。